Tarsus Pharmaceuticals (TARS) Stock Price, News, Quotes-Moomoo

US Stock MarketDetailed Quotes

TARS Tarsus Pharmaceuticals

Watchlist

48.780
-0.340-0.69%

Close Jan 24 16:00 ET

48.780
0.0000.00%

Post 17:14 ET

1.86BMarket Cap-13.01P/E (TTM)

Full Hours

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Oppenheimer Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $72
Moomoo NewsJan 22 09:33 ET · Ratings
Is Tarsus Pharmaceuticals (TARS) Among Billionaire Joseph Edelman's Long-Term Stock Picks?
Yahoo FinanceJan 20 15:31 ET
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $84
Moomoo NewsJan 15 08:33 ET · Ratings
Express News | Tarsus Provides 2025 Update: Accelerating the Launch of Xdemvy® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care
ReutersJan 13 08:30 ET
Here's Why Tarsus Pharmaceuticals (NASDAQ:TARS) Can Manage Its Debt Despite Losing Money
Simply Wall StJan 12 07:21 ET
Express News | Tarsus Pharmaceuticals Inc : BofA Global Research Raises Price Objective to $74 From $68
ReutersJan 6 08:46 ET

Comments

Jerry Kronenberg

Nov 13, 2024 15:29

Columns Tarsus Pharmaceuticals Gains Some 15% After Hours on Better-Than-Expected Q3 Results

$Tarsus Pharmaceuticals (TARS.US)$ rose some 15% in after-hours trading Wednesday after the biotech reported a narrower-than-Q3 expected loss and better-than-forecast quarterly revenues.
TARS – which makes XDEMVY, a prescription eye drop to treat optical disease Demodex blepharitis – gained 14.5% to $53.25 shortly before 4:30 p.m. ET after unveiling a $0.61 Q3 loss, beating the $0.92 that analysts had reportedly f...

MMu

Oct 29, 2024 15:16

$Tarsus Pharmaceuticals (TARS.US)$ wonder which 2 pharmas are bidding for Tarsus!!

Stock_Drift

Oct 28, 2024 04:33

Pre Market Ticks. 5:32am 10/28

$Jet.AI (JTAI.US)$ $ProShares UltraShort Bloomberg Crude Oil ETF (SCO.US)$ $Phunware (PHUN.US)$ $ImmunityBio (IBRX.US)$ $Longeveron (LGVN.US)$ $BIOSIG TECHNOLOGIES INC (BSGM.US)$ $Tarsus Pharmaceuticals (TARS.US)$ $XTL Biopharmaceuticals (XTLB.US)$ $LENZ Therapeutics (LENZ.US)$ $TC BioPharm (TCBP.US)$ $Top Wealth Group Holding (TWG.US)$ $Healthcare Triangle (HCTI.US)$ $Pixie Dust Technologies(Delisted) (PXDT.US)$
📊⚡️📊

Jaguar8

Aug 8, 2024 15:17

NEWS

$Tarsus Pharmaceuticals (TARS.US)$
Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements
Tarsus Pharmaceuticals (NASDAQ: TARS) reported strong Q2 2024 financial results, with XDEMVY® net product sales reaching $40.8 million, a 65% increase from Q1.
Year-to-date sales totaled $65.5 million.
The company delivered over 37,000 bottles to patients in Q2 and achieved an impressive gross-to-net discount of 44%.
Tarsus expanded payer coverage, incl...

Moomoo AI

Mar 1, 2024 12:53

Analysts predict Tarsus Pharmaceuticals' growth to outpace the industry with a 5x annualised growth by 2024. The upgraded price target indicates an expected increase in the business's intrinsic value.